Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 8/20 | 0.46 |
| ▸ | CA1 | P00915 | 5/20 | 0.46 |
| ▸ | NAMPT | P43490 | 1/20 | 0.37 |
| ▸ | CTSK | P43235 | 3/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.34 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.34 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.34 |
| ▸ | AKT1 | P31749 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18401386 | 0.91 | CA2 (0.49) | CA2CA1NAMPTCTSKSIGMAR1 | |
| SCHEMBL29958774 | 0.90 | CA2 (0.47) | CA2CA1NAMPTCTSKNR1H4 | |
| SCHEMBL16208966 | 0.87 | CA2 (0.49) | CA2CA1NAMPTCTSKSIGMAR1 | |
| SCHEMBL16208965 | 0.87 | CA2 (0.49) | CA2CA1NAMPTCTSKSIGMAR1 | |
| SCHEMBL12401895 | 0.84 | CA2 (0.53) | CA2CA1NAMPTCTSKSIGMAR1 | |
| SCHEMBL18401365 | 0.81 | CA2 (0.50) | CA2CA1NAMPTCTSKNR1H4 | |
| SCHEMBL8381013 | 0.78 | CA2 (0.49) | CA2CA1NAMPTCTSK | |
| SCHEMBL15684582 | 0.78 | CA2 (0.49) | CA2CA1NAMPTPTGER4 | |
| SCHEMBL24670449 | 0.77 | CA2 (0.48) | CA2CA1NAMPTCTSKPTGER4 | |
| SCHEMBL16208882 | 0.77 | CA2 (0.50) | CA2CA1NAMPTCTSKSIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250170282-A1 | COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS | LANTHEUS MEDICAL IMAGING, INC. (US) | 2025-05-29 | — | — | US | disclosed |
| US-20220339303-A1 | COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS | LANTHEUS MEDICAL IMAGING, INC. | 2022-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250170282-A1 | COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS | FABP3, TNNI3, TNNT2 | CA2 992/4885CA1 85/4885NAMPT 2707/4885 |
| US-20220339303-A1 | COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS | FABP3, TNNI3, TNNT2 | CA2 992/4885CA1 85/4885NAMPT 2707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.